Y. Sultan, MD, Coordinator, Centre des Hémophiles.
Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery
Version of Record online: 5 MAR 2003
Volume 30, Issue 5, pages 441–443, June 1990
How to Cite
Bardin, J.M. and Sultan, Y. (1990), Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion, 30: 441–443. doi: 10.1046/j.1537-2995.1990.30590296380.x
- Issue online: 5 MAR 2003
- Version of Record online: 5 MAR 2003
- Received for publication June 3, 1989; revision received November 8, 1989, and accepted November 11, 1989
Hemophilia B patients are usually treated for the prevention and control of bleeding episodes with a plasma derivative containing the four vitamin K-dependent clotting factors (PPSB). Prothrombin complex concentrate and the French PPSB concentrate are known to be thrombogenic when used in long-term treatment of surgical patients. The present study reports two cases of thrombotic episodes following surgery in PPSB-treated hemophilia B patients. Since 1986, there has been available a factor IX (FIX) concentrate depleted of the other vitamin K-dependent clotting factors and virally inactivated by the solvent-detergent method. This preparation has been used as replacement therapy in six patients with severe hemophilia B who were to undergo orthopedic surgery. The management of the patients before and after operation was without any thrombotic complication or undesirable side effects. The present study suggests that there is a need for an FIX preparation devoid of the other vitamin K-dependent clotting factors for long-term therapy of hemophilia B patients.